Effects of anidulafungin and voriconazole, singly and in combination, on cytokine/chemokine production by human monocyte-derived macrophages infected with Candida glabrata or activated by lipopolysaccharide

Chemotherapy

Volumn 58, Issue 2, 2012, Pages 146-151

  Baltch, Aldona L ^a,b   Lawrence, David ^c   Ritz, William J ^a,b   Andersen, Nancy ^c   Bopp, Lawrence H ^a,b,d   Michelsen, Phyllis B ^a,b   Carlyn, Cynthia J ^a,b   Smith, Raymond P ^a,b  

^a STRATTON VA MEDICAL CENTER   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c WADSWORTH CENTER   (United States)

^d Center for Agriculture and Natural Resources   (United States)

Author keywords

Anidulafungin; Candida glabrata; Cytokines chemokines; Human monocytes; Voriconazole

Indexed keywords

ANIDULAFUNGIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; VORICONAZOLE;

ARTICLE; CANDIDA GLABRATA; CANDIDIASIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MACROPHAGE; MONOCYTE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SUPERNATANT; SURVIVAL RATE;

ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CHEMOKINES; CYTOKINES; ECHINOCANDINS; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES; PYRIMIDINES; TRIAZOLES;

EID: 84860817380     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000337076     Document Type: Article

References (32)

1. Pfaller MA, Diekema D: Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002; 40: 3551-3557.
2. Wisplinghoff H, Bischoff T, Talent SM, Seifert H, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.
3. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyssi AJ, Marr KA, Pfaller MA, Chang CH, Webster KM: Epidemiology and outcomes of candidemia in 2019 patients: data from prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-1703.
4. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ: In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005; 43: 5425-5427.
5. Vazquez JA: Combination antifungal therapy: the new frontier. Future Microbiol 2007; 2: 115-139.
6. Sitheeque MAM, Panagoda GJ, Yau J, Amarakoon AMT, Udagama URN, Samaranayake LP: Antifungal activity of black tea polyphenols (catechins and theoflavins) against Candida species. Chemotherapy 2009; 55: 189-196.
7. Xu K, Wang H, Liu L, Xu W, Sheng J, Fan W, Yang Y-Y, Li L: Efficacy of CG 3 R 6 TAT nanoparticles self-assembled from a novel antimicrobial peptide for the treatment of Candida albicans meningitis in rabbits. Chemotherapy 2011; 57: 417-425.
8. Routh MM, Raut JS, Karuppayil SM: Dual properties of anticancer agents: an exploratory study on the in vitro anti- Candida properties of thirty drugs. Chemotherapy 2011; 57: 372-380.
9. Dale DC, Boxer L, Liles WC: The phagocytes: neutrophils and monocytes. Blood 2008; 112: 935-945.
10. Mogensen TH, Paludan SR, Kilian M, Ostergaard L: Live Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis activate the inflammatory response through Toll-like receptors 2, 4, and 9 in species-specific patterns. J Leukoc Biol 2006; 80: 267-277.
11. Baltch AL, Smith RP, Franke MA, Ritz WJ, Michelsen PB, Bopp LH: Effects of cytokines and fluconazole on the activity of human monocytes against Candida albicans. Antimicrob Agents Chemother 2001; 45: 96-104.
12. Roilides E, Walsh T: Recombinant cytokine/ chemokines in augmentation and immunomodulation of host defenses against Candida spp. Med Mycol 2004; 42: 1-13.
13. Traynor TR, Huffnagle GB: Role of chemokines in fungal infections. Med Mycol 2001; 39: 41-50.
14. Rodriguez-Adrian LJ, Grazziutti ML, Rex JH, Anaissie EJ: The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis 1998; 26: 1270-1278.
15. Pinsky MR, Vincent J-L, Alegra M, Dupont E: Serum cytokine levels in human septic shock; relation to multiple-system organ failure and mortality. Chest 1993; 103: 565-575.
16. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude RL, Angus DC, for the GenIMS Investigators: Understanding the inflammatory cytokine response in pneumonia and sepsis; results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007; 167: 1061-1067.
17. Stevens DL: Immune modulatory effects of antibiotics. Curr Opin Infect Dis 1996; 9: 165-169.
18. Labro MT: Immunological effects of macrolides. Curr Opin Infect Dis 1998; 11: 681-688.
19. Choi JH, Song MJ, Kim SH, Choi SM, Lee DG, Yoo JH, Shin WS: Effect of moxifloxacin on production of pro-inflammatory cytokines from human peripheral blood mononuclear cells. Antimicrob Agents Chemother 2003; 47: 3704-3707.
20. Mogensen TH: Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2009; 22: 240-273.
21. Ben-Ami R, Lewis RE, Kontoyiannis DP: Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis 2008; 47: 226-235.
22. Casadevall A, Pirofski LA: Adjunctive immune therapy for fungal infections. Clin Infect Dis 2001; 33: 1048-1056.
23. Netea MG, Gow NA, Munro CA, Bates S, Collins C, Ferwerda, G, Hobson RP, Bertram G, Hughes HB, Jansen T, Jacobs L, Buurman ET, Gijzen K, Williams DL, Torensma R, McKinnon A, MacCallum DM, Odds FC, Van der Meer JW, Brown AJ, Kullberg BJ: Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest 2006; 116: 1642-1650.
24. Stevens DA: A possible mechanism for synergy between antifungal therapy and immune defenses. J Infect Dis 2008; 198: 159-162.
25. Clinical Laboratory Standards Institute: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard M27-A3, ed 3. Wayne, Clinical Laboratory Standards Institute, 2008.
26. Stuart A, Ord JK: Kendall's Advanced Theory of Statistics. New York, Oxford University Press, 1991, vol 2, pp 1139, 1149.
27. Nakagawa T, Ohno N, Murai T: Suppression by Candida albicans β-glucan of cytokine release from activated human monocytes and from T cells in the presence of monocytes. J Infect Dis 2003; 187: 710-713.
28. Brown GD, Gordon S: Fungal beta-glucans and mammalian immunity. Immunity 2003; 19: 311-315.
29. Brown GD, Gordon S: Immune recognition of fungal beta-glucans. Cell Microbiol 2005; 7: 471-479.
30. Kinoshita K, Iwasaki H, Uzui H, Ueda T: Candin family antifungal agent micafungin (FK463) modulates the inflammatory cytokine/chemokine production, stimulated by lipopolysaccharide in THP-1 cells. Transl Res 2006; 148: 207-213.
31. Rutkowski DT, Kaufman RJ: A trip to the ER: coping with stress. Trends Cell Biol 2004; 14: 2000-2028.
32. Rapp UK, Kaufmann SHE: Glucose-regulated stress proteins and antibacterial immunity. Trends Microbiol 2003; 11: 519-525.